Release Date: December 3, 2025
Expiration Date: January 7, 2026
Activity Overview
Recent advances in molecular testing and targeted therapies have rapidly transformed care for non–small cell lung cancer (NSCLC), making personalized management possible across all disease stages. However, significant challenges persist in the early detection of actionable mutations, comprehensive biomarker testing, and the integration of novel agents with unique efficacy and toxicity profiles into everyday practice.
This live webinar series brings together expert faculty for interactive, case-based discussions tailored to community oncology practice. Participants will gain practical insights on implementing biomarker-driven strategies, selecting optimal therapies, and managing adverse events, enhancing confidence in advancing NSCLC care for diverse patient populations.
This educational activity is an archive of the live presentation held on November 20, 2025.
Target Audience
This educational program is primarily directed toward community-based oncologists involved in the treatment of NSCLC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate key biomarkers and their role in guiding targeted therapy selection in NSCLC
- Implement molecular testing strategies to identify actionable mutations in clinical practice
- Apply clinical trial evidence supporting the efficacy and safety of targeted therapies in NSCLC to manage patients with NSCLC with actionable mutations optimally
- Identify optimal strategies to manage adverse events associated with novel targeted therapies in NSCLC
Charu Aggarwal, MD, MPH, FASCO
Leslye M. Heisler Professor for Lung Cancer Excellence
Associate Director, Penn Center for Cancer Care Innovation (PC3I)
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA
Disclosures: Consultant: AbbVie, AstraZeneca, Daiichi Sankyo/AstraZeneca, Gilead Sciences, Novocure, Pfizer; Grant/Research Funding (to institution): AstraZeneca/MedImmune, Candel Therapeutics, Daichi Sankyo/AstraZeneca, Genmab, Loxo@Lilly, Merck Sharp & Dohme; Speaker’s Bureau (to an immediate family member): AstraZeneca
Philip A. Haddad, MD, MPH, MHA, MS(HCI)
Chief of Hematology-Oncology Section/ACOS-Chief of Research
Overton Brooks VAMC
Professor of Medicine
LSU HSC-S Department of Medicine
Feist-Weiller Cancer Center
Shreveport, LA
Disclosures: Philip A. Haddad, MD, MPH, MHA, MS(HCI) has no relevant financial relationships with ineligible companies.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here